Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. AtkinsDavid F. McDermott

Cancer Epigenetics Institute
Hematology Oncology
Nuclear Dynamics and Cancer (NDC)

Dana-Farber Cancer Institute
Harvard University
Queen Mary University of London
Memorial Sloan-Kettering Cancer Center
University of Texas Health Science Center at Houston
Niigata University
Vanderbilt University
University of Texas Southwestern Medical Center
Université Paris-Sud
Bristol-Myers Squibb
Georgetown University
Dana-Farber/Harvard Cancer Center

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Sort by
Weight
Alphabetically

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Fingerprint

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science